Moreover, activating mutations of TCF3 and FOXO1, inactivating mutations of TCF3 antagonist ID3, and protein stabilizing mutations of CCND3 belong to the most frequent oncogenic events in BL [10,11,12]. This evidence concerns the gene CCND3 and Burkitt lymphoma.